No. |
DrugBank |
薬物名(臨床試験情報から抽出) |
KEGG DRUG * | KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 | Amlodipine | 4件: Amlodipine; Amlodipine (drug); Amlodipine gel; Calcium channel blockers (amlodipine, azelnidipine); | D00615 D02914 D07450 |
4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S |
34件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
4件: 51, 65, 67, 298 |
2 | Bardoxolone | 4件: Bardoxolone; Bardoxolone methyl; Bardoxolone methyl capsules; Bardoxolone methyl oral capsule; | D09584 |
- |
- |
7件: 66, 67, 84, 85, 86, 218, 222 |
3 | Bardoxolone methyl | 3件: Bardoxolone methyl; Bardoxolone methyl capsules; Bardoxolone methyl oral capsule; | D09585 |
- |
- |
7件: 66, 67, 84, 85, 86, 218, 222 |
4 | Bendroflumethiazide | 1件: Bendroflumethiazide; | D00650 |
- |
- |
1件: 67 |
5 | Bisoprolol | 2件: Bisoprolol; Bisoprolol fumarate; | D00634 D02342 |
1件: ADRB1 |
10件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
3件: 67, 86, 113 |
6 | Bosutinib | 1件: Bosutinib; | D03252 |
2件: ABL1, SRC |
45件: Adherens junction, Axon guidance, Bacterial invasion of epithelial cells, Bladder cancer, C-type lectin receptor signaling pathway, Cell cycle, Chemokine signaling pathway, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, GABAergic synapse, Gap junction, GnRH signaling pathway, Hepatitis B, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, Kaposi sarcoma-associated herpesvirus infection, MicroRNAs in cancer, Mitophagy - animal, Neurotrophin signaling pathway, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Prolactin signaling pathway, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis, Thyroid hormone signaling pathway, Tight junction, Tuberculosis, VEGF signaling pathway, Viral carcinogenesis, Viral myocarditis, Yersinia infection |
2件: 2, 67 |
7 | Candesartan | 1件: Candesartan; | D00522 |
1件: AGTR1 |
14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
2件: 58, 67 |
8 | Candesartan cilexetil | - | D00522 D00626 |
1件: AGTR1 |
14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
2件: 58, 67 |
9 | Cilnidipine | 1件: Cilnidipine; | D01173 |
5件: CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1S |
37件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Morphine addiction, Nicotine addiction, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Synaptic vesicle cycle, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 67 |
10 | Curcumin | 5件: Bio-enhanced curcumin soft gelatin capsule; Curcumin; Curcumin (longvida™); Curcumin supplement; Ifn beta 1 a + curcumin (bcm 95); | - |
- |
- |
10件: 13, 46, 49, 67, 74, 94, 96, 97, 139, 299 |
11 | Doxazosin | 2件: Doxazosin; Metoprolol succinate + doxazosin; | D00608 D07874 |
3件: ADRA1A, ADRA1B, ADRA1D |
7件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
2件: 57, 67 |
12 | Emodin | 1件: Emodin; | - |
- |
- |
1件: 67 |
13 | Everolimus | 6件: Afinitor (everolimus); Everolimus; Everolimus (rad001); Everolimus (rad001) , afinitor®; Rad001, everolimus; Rad001: everolimus; | D02714 |
1件: MTOR |
43件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 |
14 | Hydralazine | 1件: Hydralazine; | D01302 D08044 |
1件: AOC3 |
5件: Glycine, serine and threonine metabolism, Metabolic pathways, Phenylalanine metabolism, Tyrosine metabolism, beta-Alanine metabolism |
1件: 67 |
15 | Hydrochlorothiazide | 2件: Hydrochlorothiazide; Hydrochlorothiazide/amiloride; | D00340 |
- |
- |
3件: 13, 67, 225 |
16 | Imidapril | 1件: Imidapril; | D08068 |
1件: ACE |
4件: Chagas disease (American trypanosomiasis), Hypertrophic cardiomyopathy (HCM), Renin secretion, Renin-angiotensin system |
1件: 67 |
17 | L-Arginine | 3件: L-arginine; Ng-monomethyl-l-arginine; Ng-monomethyl-l-arginine (drug); | D02982 |
- |
- |
5件: 67, 78, 113, 251, 299 |
18 | Lanreotide | 2件: Lanreotide; Lanreotide acetate; | D04666 |
- |
- |
4件: 67, 73, 85, 298 |
19 | Lisinopril | 3件: Coenzyme q10 and lisinopril; Lisinopril; Lisinopril, losartan, and atorvastatin; | D00362 D08131 |
1件: ACE |
4件: Chagas disease (American trypanosomiasis), Hypertrophic cardiomyopathy (HCM), Renin secretion, Renin-angiotensin system |
5件: 46, 66, 67, 113, 222 |
20 | Lixivaptan | 1件: Lixivaptan; | D04752 |
1件: AVPR2 |
3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
1件: 67 |
21 | Losartan | 8件: Lisinopril, losartan, and atorvastatin; Losartan; Losartan and atenolol or propranolol; Losartan bluefish 50 mg; Losartan potasico; Losartan potassium; Losartan tablets & qingremoshen granule; Sildenafil and losartan; | D00357 D08146 |
1件: AGTR1 |
14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
18件: 13, 17, 19, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 |
22 | Metformin | 12件: 750 mg metformin and 7.5 g l-citrulline daily p.o.; Glucophage (metformin); L-citrulline and metformin & l-citrulline; Metformin; Metformin (generic); Metformin 500mg; Metformin and metformin & l-citrulline; Metformin hcl; Metformin hydrochloride; Metformin/cp-690,550; Pioglitazone or metformin; Sitagliptin and metformin; | D00944 D04966 |
2件: PRKAA1, PRKAA2 |
19件: AMPK signaling pathway, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy (HCM), Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease (NAFLD), Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway |
17件: 6, 13, 46, 49, 67, 75, 77, 81, 86, 113, 158, 206, 225, 233, 265, 285, 299 |
23 | Nicotinamide | 2件: Nicotinamide; Nicotinamide riboside; | D00036 |
- |
- |
8件: 5, 6, 13, 46, 49, 53, 67, 162 |
24 | Octreotide | 5件: Gallium-68-dota-n-octreotide; Octreotide; Octreotide lar; Octreotide lar / sandostatin lar (lar=long acting release); Octreotide-lar; | D00442 D06495 |
1件: SSTR2 |
4件: Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
8件: 67, 75, 84, 85, 89, 96, 193, 227 |
25 | Pasireotide | 7件: Pasireotide; Pasireotide 0.6 mg/ml; Pasireotide diaspartate; Pasireotide lar; Pasireotide pamoate; Pasireotide s.c.; Pasireotide with or without cabergoline; | D10147 |
4件: SSTR1, SSTR2, SSTR3, SSTR5 |
4件: Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
3件: 67, 74, 75 |
26 | Pioglitazone | 6件: Actos (pioglitazone); Pioglitazone; Pioglitazone 15 mg; Pioglitazone and tretinoin; Pioglitazone or metformin; Tretinoin and pioglitazone hcl; | D00945 D08378 |
1件: PPARG |
9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
17件: 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
27 | Potassium | 4件: Losartan potassium; Potassium; Potassium sparing diuretic; Potassium supplement; | D08403 |
- |
- |
9件: 46, 66, 67, 98, 115, 167, 179, 215, 235 |
28 | Pravastatin | 4件: Lonafarnib, zoledronic acid, and pravastatin; Montelukast, flurbiprofen, midazolam, digoxin, pravastatin and bms-986142; Pravastatin; Pravastatin sodium; | D00893 D08410 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
9件: 13, 46, 49, 67, 79, 96, 164, 265, 333 |
29 | Ramipril | 1件: Ramipril; | D00421 |
1件: ACE |
4件: Chagas disease (American trypanosomiasis), Hypertrophic cardiomyopathy (HCM), Renin secretion, Renin-angiotensin system |
7件: 46, 49, 66, 67, 113, 218, 257 |
30 | Sirolimus | 14件: Rapamycin, sirolimus; Sirolimus; Sirolimus (formerly known as rapamycin); Sirolimus 0,1% crème; Sirolimus 0.2%; Sirolimus 0.4%; Sirolimus 2 mg; Sirolimus 2%; Sirolimus and hydroxychloroquine; Sirolimus oral liquid product 1mg/ml; Sirolimus, 2%; Skincerity plus sirolimus/rapamycin; Skinercity plus sirolimus/rapamycin; Topical 0.1% sirolimus; | D00753 |
1件: MTOR |
43件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
31 | Sodium chloride | 14件: 0.9% sodium chloride; 0.9% sodium chloride (normal saline); 0.9% sodium chloride injection; 0.9% w/v sodium chloride solution; Isotonic sodium chloride solution; Physiological serum (sodium chloride); Sodium chloride; Sodium chloride (7%); Sodium chloride 0,9%; Sodium chloride 6%; Sodium chloride solution; Sodium chloride solution 0.9%; Sodium chloride solvent; Sodium pyruvate in 0.9% sodium chloride solution; | D02056 |
- |
- |
19件: 6, 11, 13, 14, 17, 34, 46, 51, 53, 67, 78, 86, 97, 168, 193, 227, 228, 288, 299 |
32 | Somatostatin | 2件: Long-acting somatostatin; Somatostatin; | D07431 |
5件: SSTR1, SSTR2, SSTR3, SSTR4, SSTR5 |
4件: Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
2件: 67, 78 |
33 | Spironolactone | 4件: Ambrisentan plus spironolactone; Spironolactone; Spironolactone and conivaptan; Spironolactone captopril carvedilol; | D00443 |
1件: NR3C2 |
1件: Aldosterone-regulated sodium reabsorption |
6件: 58, 67, 86, 113, 218, 225 |
34 | Telmisartan | 1件: Telmisartan; | D00627 |
1件: AGTR1 |
14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
2件: 66, 67 |
35 | Tesevatinib | 2件: Kd019 (tesevatinib); Tesevatinib; | - |
- |
- |
1件: 67 |
36 | Tilarginine | - | - |
- |
- |
1件: 67 |
37 | Tolvaptan | 15件: Jinarc - tolvaptan tablets; Opc-41061 (tolvaptan); Tolvaptan; Tolvaptan (opc-41061); Tolvaptan 15 mg tablet; Tolvaptan 15 mg tablets; Tolvaptan 15mg; Tolvaptan 30 mg tablet; Tolvaptan 30 mg tablets; Tolvaptan 30mg; Tolvaptan 7.5 mg tablet; Tolvaptan in euvolemic hyponatremia; Tolvaptan ir; Tolvaptan mr; Tolvaptan oral tablet; | D01213 |
1件: AVPR2 |
3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
3件: 67, 72, 225 |
38 | Tripterygium wilfordii whole | - | - |
- |
- |
8件: 46, 66, 67, 96, 162, 222, 224, 271 |
39 | Triptolide | 2件: Triptolide; Triptolide-containing formulation; | - |
- |
- |
1件: 67 |
40 | Ursodeoxycholic acid | 9件: Udca (ursodeoxycholic acid); Ursodeoxycholic acid; Ursodeoxycholic acid (udca); Ursodeoxycholic acid (urso); Ursodeoxycholic acid 300mg capsule; Ursodeoxycholic acid 300mg tablet; Ursodeoxycholic acid capsules; Ursodeoxycholic acid combination of immunosuppressive agents; Ursodiol (ursodeoxycholic acid, udca); | D00734 |
1件: NR1H4 |
1件: Bile secretion |
12件: 6, 8, 20, 67, 84, 93, 94, 95, 96, 97, 234, 299 |
41 | Venglustat | 3件: Venglustat; Venglustat gz/sar402671; Venglustat gz402671; | D11633 |
1件: UGCG |
2件: Metabolic pathways, Sphingolipid metabolism |
2件: 19, 67 |
42 | Water | 13件: 15 o water; 15-o labeled water; 5% glucose water solution; Dextrose, 5% in water; High water intake; Lactose in water; Pl 12185/0002 & pl 12185/0005(water for injection); Pseudoephedrine + 480 ml water; Pseudoephedrine + 50 ml water; Water; Water for injection; Water for injections; Water for injections, ep; | D00001 |
- |
- |
22件: 2, 5, 6, 13, 17, 19, 28, 35, 46, 53, 57, 63, 65, 67, 78, 84, 97, 193, 226, 271, 278, 299 |